These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 33140101)

  • 21. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
    Ott PA; Hodi FS; Robert C
    Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response.
    Dimitriou F; Zaremba A; Allayous C; Kähler KC; Gerard CL; Festino L; Schäfer S; Toussaint F; Heinzerling L; Hassel JC; Ascierto PA; Michielin O; Hauschild A; Lebbe C; Livingstone E; Ramelyte E; Cheng PF; Dummer R; Mangana J
    Eur J Cancer; 2021 May; 149():37-48. PubMed ID: 33823361
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of late concurrent hypofractionated radiotherapy in advanced melanoma patients failing anti-PD-1 monotherapy.
    Funck-Brentano E; Baghad B; Fort M; Aouidad I; Roger A; Beauchet A; Otmezguine Y; Blom A; Longvert C; Boru B; Saiag P
    Int J Cancer; 2020 Sep; 147(6):1707-1714. PubMed ID: 32083739
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biological Factors behind Melanoma Response to Immune Checkpoint Inhibitors.
    Olbryt M; Rajczykowski M; Widłak W
    Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32517213
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunotherapy discontinuation - how, and when? Data from melanoma as a paradigm.
    Robert C; Marabelle A; Herrscher H; Caramella C; Rouby P; Fizazi K; Besse B
    Nat Rev Clin Oncol; 2020 Nov; 17(11):707-715. PubMed ID: 32636502
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Treatment of melanoma with immune checkpoints inhibitors].
    Lupu J; Hamann P; Routier É; Robert C
    Rev Prat; 2021 Apr; 71(4):380-383. PubMed ID: 34161002
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Determinants of overall survival in patients with metastatic uveal melanoma.
    Demkowicz P; Pointdujour-Lim R; Miguez S; Lee Y; Jones BSCL; Barker CA; Bosenberg M; Abramson DH; Shoushtari AN; Kluger H; Francis JH; Sznol M; Bakhoum MF
    Cancer; 2023 Oct; 129(20):3275-3286. PubMed ID: 37382208
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry.
    Cho J; Ahn S; Yoo KH; Kim JH; Choi SH; Jang KT; Lee J
    Invest New Drugs; 2016 Dec; 34(6):677-684. PubMed ID: 27491654
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent advances in tyrosine kinase inhibitors VEGFR 1-3 for the treatment of advanced metastatic melanoma.
    Sobczuk P; Cholewiński M; Rutkowski P
    Expert Opin Pharmacother; 2024 Apr; 25(5):501-510. PubMed ID: 38607407
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical Outcomes of Immune Checkpoint Blocker Therapy for Malignant Melanoma in Korean Patients: Potential Clinical Implications for a Combination Strategy Involving Radiotherapy.
    Lee J; Chang JS; Roh MR; Jung M; Lee CK; Oh BH; Chung KY; Koom WS; Shin SJ
    Cancer Res Treat; 2020 Jul; 52(3):730-738. PubMed ID: 32054150
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adjuvant anti-PD1 immunotherapy of resected skin melanoma: an example of non-personalized medicine with no overall survival benefit.
    Ochenduszko S; Puskulluoglu M; Pacholczak-Madej R; Ruiz-Millo O
    Crit Rev Oncol Hematol; 2024 Oct; 202():104443. PubMed ID: 39025250
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systemic and liver-directed therapies in metastatic uveal melanoma: state-of-the-art and novel perspectives.
    Comito F; Marchese PV; Ricci AD; Tober N; Peterle C; Sperandi F; Melotti B
    Future Oncol; 2021 Nov; 17(33):4583-4606. PubMed ID: 34431316
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MEK inhibitors combined with programmed cell death-1 blockade immunotherapy for metastatic uveal melanoma: is it warranted?
    Zanella A; Doussot A; Puzenat E; Aubin F; Nardin C
    Melanoma Res; 2020 Dec; 30(6):606-607. PubMed ID: 32590414
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.
    Kreft S; Gesierich A; Eigentler T; Franklin C; Valpione S; Ugurel S; Utikal J; Haferkamp S; Blank C; Larkin J; Garbe C; Schadendorf D; Lorigan P; Schilling B
    Eur J Cancer; 2019 Jul; 116():207-215. PubMed ID: 31212163
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.
    Algazi AP; Tsai KK; Shoushtari AN; Munhoz RR; Eroglu Z; Piulats JM; Ott PA; Johnson DB; Hwang J; Daud AI; Sosman JA; Carvajal RD; Chmielowski B; Postow MA; Weber JS; Sullivan RJ
    Cancer; 2016 Nov; 122(21):3344-3353. PubMed ID: 27533448
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investigating the role of immunotherapy in advanced/recurrent female genital tract melanoma: a preliminary experience.
    Indini A; Di Guardo L; Cimminiello C; Lorusso D; Raspagliesi F; Del Vecchio M
    J Gynecol Oncol; 2019 Nov; 30(6):e94. PubMed ID: 31576688
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Survival analysis of comprehensive treatment in Chinese patients with metastatic melanoma: A retrospective analysis.
    Chen Q; Zhao Y; Li P; Duan J; Fu X; Tang Y; Ma Y; Zhou Q
    Skin Res Technol; 2024 Feb; 30(2):e13546. PubMed ID: 38279601
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel Approaches to the Systemic Management of Uveal Melanoma.
    Khan S; Carvajal RD
    Curr Oncol Rep; 2020 Jul; 22(10):104. PubMed ID: 32725406
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunotherapy With Programmed Cell Death 1 Inhibitors for 5 Patients With Conjunctival Melanoma.
    Sagiv O; Thakar SD; Kandl TJ; Ford J; Sniegowski MC; Hwu WJ; Esmaeli B
    JAMA Ophthalmol; 2018 Nov; 136(11):1236-1241. PubMed ID: 30352118
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pembrolizumab as first-line treatment for metastatic uveal melanoma.
    Rossi E; Pagliara MM; Orteschi D; Dosa T; Sammarco MG; Caputo CG; Petrone G; Rindi G; Zollino M; Blasi MA; Cassano A; Bria E; Tortora G; Schinzari G
    Cancer Immunol Immunother; 2019 Jul; 68(7):1179-1185. PubMed ID: 31175402
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.